Revance Therapeutics Current Cash

Revance Therapeutics (RVNC) currently reports a current cash of $59M as of September 2024. That compares with $180M in the prior-year period — down 67.3% year over year. Use the charts on this page to explore Revance Therapeutics's current cash history and peer comparisons.

Revance Therapeutics's current cash decreased from $180M to $59M — a 67.3% year-over-year decrease (period ending September 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Revance Therapeutics reported $59M in current cash as of September 2024. That compares with $180M in the prior-year period — down 67.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current current cash of $59M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Revance Therapeutics, and consider following RVNC for alerts when major investors trade the stock.

Revance Therapeutics is classified in the Healthcare sector. On current cash, it currently shows $59M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing RVNC with unrelated industries.